The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The Food and Drug Administration has approved the Novavax COVID-19 vaccine—with strict conditions. Coming after four years of ...

Political alignments worldwide are in a state of flux. Japan is no exception. In recent years, Haraguchi Kazuhiro, a member ...

The US Food and Drug Administration (FDA) has approved Novavax's Covid-19 vaccine, Nuvaxovid, but only for limited use in ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.

The GOP-led House Judiciary Committee is investigating allegations that Pfizer delayed its COVID-19 vaccine testing until ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Pfizer also beat analyst expectations for first-quarter earnings as it benefited from cost-saving efforts, although it fell short of Wall Street’s revenue estimate, as sales of its COVID-19 ...